MedTrace Logo

Spironolactone for the Treatment of Melasma

NCT03953209 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2024-09-04

No results posted yet for this study

Summary

The purpose of this study is to prospectively gather data on the efficacy and tolerability of spironolactone to treat refractory melasma and to compare treatment response of randomized 50 mg, 100mg, and 200mg per day dosing.

Conditions

  • Melasma

Interventions

DRUG

Spironolactone 50Mg Tablet

Oral administration of one spironolactone 50 mg tablet once daily for 12 weeks

DRUG

Spironolactone 100Mg Tablet

Oral administration of one spironolactone 100 mg tablet once daily for 12 weeks

DRUG

Spironolactone 200Mg

Oral administration of two spironolactone 100 mg tablets once daily for 12 weeks

Sponsors & Collaborators

  • Medical University of South Carolina

    lead OTHER

Principal Investigators

  • Dirk Elston, MD · Medical University of South Carolina

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-05
Primary Completion
2021-01-01
Completion
2021-01-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03953209 on ClinicalTrials.gov